Our immuno-molecular classification scheme supplemented with NSMP tumor sub-grouping based on the ARID1A and CTNNB1 status granted a more reliable risk assessment and it resulted to be particularly informative in the group of high-risk patients. This evidence concerns the gene ARID1A and neoplasm.